Novelion

NVLN-T

0.00
0.00 (0.00%)
This company is not ACTIVE.

Analysis and Opinions about NVLN-T

Signal
Opinion
Expert
BUY
BUY
January 17, 2005
Closed their merger in December, so hopefully the share price indigestion that comes with mergers is over. Fundamentally not expensive, Chart is interesting. Balance sheet is in good shape. His holdings is on a paired/trade situation with a short on Eyetech (EYET-Q). Very beaten up stock, but has some decent prospects.
Show full opinionHide full opinion
Novelion (NVLN-T)
January 17, 2005
Closed their merger in December, so hopefully the share price indigestion that comes with mergers is over. Fundamentally not expensive, Chart is interesting. Balance sheet is in good shape. His holdings is on a paired/trade situation with a short on Eyetech (EYET-Q). Very beaten up stock, but has some decent prospects.
BUY
BUY
January 7, 2005
Strong balance sheet. Outlook for the sale of their product is quite encouraging.
Show full opinionHide full opinion
Novelion (NVLN-T)
January 7, 2005
Strong balance sheet. Outlook for the sale of their product is quite encouraging.
DON'T BUY
DON'T BUY
December 23, 2004
Has had a disappointing year. Some competitive drugs have been approved by the FDA which will attack part of its market share. Growth profile for the next couple of years is not that strong.
Show full opinionHide full opinion
Novelion (NVLN-T)
December 23, 2004
Has had a disappointing year. Some competitive drugs have been approved by the FDA which will attack part of its market share. Growth profile for the next couple of years is not that strong.
BUY
BUY
December 17, 2004
Recently made an intelligent acquisition that diversified the product base. Market didn't see it that way, but over time, it should strengthen the price of QLT.
Show full opinionHide full opinion
Novelion (NVLN-T)
December 17, 2004
Recently made an intelligent acquisition that diversified the product base. Market didn't see it that way, but over time, it should strengthen the price of QLT.
DON'T BUY
DON'T BUY
December 1, 2004
Dropped below the 200 day moving average.
Show full opinionHide full opinion
Novelion (NVLN-T)
December 1, 2004
Dropped below the 200 day moving average.
VAGUE
VAGUE
November 25, 2004
Facing some competition which is worrisome. In the smaller end of the ocular market and would prefer companies in the other end.
Show full opinionHide full opinion
Novelion (NVLN-T)
November 25, 2004
Facing some competition which is worrisome. In the smaller end of the ocular market and would prefer companies in the other end.
DON'T BUY
DON'T BUY
November 11, 2004
Not too bullish on the stock, but wouldn't necessarily sell it if you own. Their key drug Visudine is facing some competition. Upside could be limited in the short term.
Show full opinionHide full opinion
Novelion (NVLN-T)
November 11, 2004
Not too bullish on the stock, but wouldn't necessarily sell it if you own. Their key drug Visudine is facing some competition. Upside could be limited in the short term.
TOP PICK
TOP PICK
November 9, 2004
Their Visudine product is a leader with the highest market share in the last few months. Their prostate cancer product will be significant. Attractive valuation. Has cash.
Show full opinionHide full opinion
Novelion (NVLN-T)
November 9, 2004
Their Visudine product is a leader with the highest market share in the last few months. Their prostate cancer product will be significant. Attractive valuation. Has cash.
BUY
BUY
November 8, 2004
Has not been a big winner over the last year, but thinks it's going to do pretty well. Likes its product.
Show full opinionHide full opinion
Novelion (NVLN-T)
November 8, 2004
Has not been a big winner over the last year, but thinks it's going to do pretty well. Likes its product.
DON'T BUY
DON'T BUY
October 20, 2004
Has a great product for dealing with macular degeneration but has had some very disappointing clinical results. Increasing competition in their product. Too expensive.
Show full opinionHide full opinion
Novelion (NVLN-T)
October 20, 2004
Has a great product for dealing with macular degeneration but has had some very disappointing clinical results. Increasing competition in their product. Too expensive.
WEAK BUY
WEAK BUY
September 17, 2004
Competition has a product that has more application for macular degeneration. A little bit of a gamble, but is certainly a popular application.
Show full opinionHide full opinion
Novelion (NVLN-T)
September 17, 2004
Competition has a product that has more application for macular degeneration. A little bit of a gamble, but is certainly a popular application.
DON'T BUY
DON'T BUY
September 16, 2004
Not a contrarian stock. Still in the sexy kind of biotech miracle cure stage. Got way ahead of itself. Have a lot of egss in one basket which makes them vulnerable. A lot of competition. Needs to be cheaper and more product diversification.
Show full opinionHide full opinion
Novelion (NVLN-T)
September 16, 2004
Not a contrarian stock. Still in the sexy kind of biotech miracle cure stage. Got way ahead of itself. Have a lot of egss in one basket which makes them vulnerable. A lot of competition. Needs to be cheaper and more product diversification.
DON'T BUY
DON'T BUY
September 14, 2004
Vrey volatile. In the health care sector, would look more to the US, such as Johnson & Johnson.
Show full opinionHide full opinion
Novelion (NVLN-T)
September 14, 2004
Vrey volatile. In the health care sector, would look more to the US, such as Johnson & Johnson.
DON'T BUY
DON'T BUY
September 8, 2004
Revenues and earnings are doing pretty well. Trades at about 18 X earnings. A lot of cash. Involved in a questionable acquisition in the US. Some competition. We'll continue to stall in the foreseeable future.
Show full opinionHide full opinion
Novelion (NVLN-T)
September 8, 2004
Revenues and earnings are doing pretty well. Trades at about 18 X earnings. A lot of cash. Involved in a questionable acquisition in the US. Some competition. We'll continue to stall in the foreseeable future.
VAGUE
VAGUE
August 26, 2004
More competitions coming in. It is a great business. At this level, the stock is reasonably attractive. However, up and downs for this stock is limited.
Show full opinionHide full opinion
Novelion (NVLN-T)
August 26, 2004
More competitions coming in. It is a great business. At this level, the stock is reasonably attractive. However, up and downs for this stock is limited.
Showing 16 to 30 of 190 entries